Stammdaten
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
Unternehmen & Branche
| Name | Tivic Health Systems, Inc. |
|---|---|
| Ticker | TIVC |
| CIK | 0001787740 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,1 Mio. USD |
| Beta | 1,84 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -8,878,000 | 31,607,000 | 16,797,000 | ||
| 2025-09-30 | 10-Q | 146,000 | -2,596,000 | 6,229,000 | 5,591,000 | |
| 2025-06-30 | 10-Q | 86,000 | -1,931,000 | -2.19 | 4,508,000 | 3,687,000 |
| 2025-03-31 | 10-Q | 70,000 | -1,502,000 | -2.52 | 3,777,000 | 3,036,000 |
| 2024-12-31 | 10-K | 780,000 | -5,655,000 | -19.68 | 2,807,000 | 2,535,000 |
| 2024-09-30 | 10-Q | 126,000 | -1,431,000 | -0.23 | 3,394,000 | 2,834,000 |
| 2024-06-30 | 10-Q | 140,000 | -1,266,000 | -5.37 | 4,783,000 | 4,192,000 |
| 2024-03-31 | 10-Q | 334,000 | -1,481,000 | -17.15 | 3,286,000 | 2,153,000 |
| 2023-12-31 | 10-K | 1,176,000 | -8,244,000 | -176.80 | 5,157,000 | 3,580,000 |
| 2023-09-30 | 10-Q | 282,000 | -1,760,000 | -1.48 | 7,007,000 | 5,765,000 |
| 2023-06-30 | 10-Q | 161,000 | -2,125,000 | -7.16 | 4,596,000 | 3,161,000 |
| 2023-03-31 | 10-Q | 376,000 | -2,116,000 | -10.52 | 7,101,000 | 5,205,000 |
| 2022-12-31 | 10-K | 1,840,000 | -10,096,000 | -104.32 | 5,875,000 | 3,630,000 |
| 2022-09-30 | 10-Q | 477,000 | -2,584,000 | -27.00 | 8,208,000 | 5,772,000 |
| 2022-06-30 | 10-Q | 528,000 | -3,018,000 | -0.32 | 11,026,000 | 8,187,000 |
| 2022-03-31 | 10-Q | 428,000 | -2,240,000 | -0.23 | 12,694,000 | 11,093,000 |
| 2022-01-31 | 10-Q | 428,000 | -2,240,000 | -0.23 | ||
| 2021-12-31 | 10-K | 1,257,000 | -8,494,000 | -2.43 | 15,036,000 | 13,272,000 |
| 2021-09-30 | 10-Q | 277,000 | -2,320,000 | -0.90 | -5,792,000 | |
| 2021-06-30 | 10-Q | 268,000 | -1,094,000 | -0.46 | -3,603,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Bolton Sheryle | Director | Open Market Purchase | 10,000 | 1.04 | 10,400.00 | +73,2% | |
| 2026-04-01 | Valauri Christina Rizopoulos | Director | Open Market Purchase | 19,000 | 0.95 | 18,008.20 | +126,8% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.